These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 30663547)

  • 21. Voriconazole: a new triazole antifungal agent.
    Johnson LB; Kauffman CA
    Clin Infect Dis; 2003 Mar; 36(5):630-7. PubMed ID: 12594645
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of drug-resistant Aspergillus infection.
    Aigner M; Lass-Flörl C
    Expert Opin Pharmacother; 2015; 16(15):2267-70. PubMed ID: 26328502
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Successful challenge of voriconazole in a patient with posaconazole-associated minor drug eruption: A case report.
    Weeraphon B; Vanichanan J; Usayaporn S
    J Clin Pharm Ther; 2020 Dec; 45(6):1486-1488. PubMed ID: 32686229
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent.
    Nagappan V; Deresinski S
    Clin Infect Dis; 2007 Dec; 45(12):1610-7. PubMed ID: 18190324
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical efficacy of new antifungal agents.
    Kauffman CA
    Curr Opin Microbiol; 2006 Oct; 9(5):483-8. PubMed ID: 16904366
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A case report of intravenous posaconazole in hepatic and renal impairment patient with invasive Aspergillus terreus infection: safety and role of therapeutic drug monitoring.
    Dilokpattanamongkol P; Panusitthikorn P; Boonprasert R; Chayakulkeeree M; Rotjanapan P
    BMC Pharmacol Toxicol; 2017 Jan; 18(1):8. PubMed ID: 28143591
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Triazole antifungals: a review.
    Peyton LR; Gallagher S; Hashemzadeh M
    Drugs Today (Barc); 2015 Dec; 51(12):705-18. PubMed ID: 26798851
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Posaconazole.
    Dodds Ashley ES; Alexander BD
    Drugs Today (Barc); 2005 Jun; 41(6):393-400. PubMed ID: 16110346
    [TBL] [Abstract][Full Text] [Related]  

  • 29.
    Thompson GR; Chang D; Wittenberg RR; McHardy I; Semrad A
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28533238
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety of triazole antifungal drugs in patients with cancer.
    Cronin S; Chandrasekar PH
    J Antimicrob Chemother; 2010 Mar; 65(3):410-6. PubMed ID: 20035021
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Posaconazole: SCH 56592.
    Adis International Ltd
    Drugs R D; 2003; 4(4):258-63. PubMed ID: 12848593
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Voriconazole and posaconazole improve asthma severity in allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization.
    Chishimba L; Niven RM; Cooley J; Denning DW
    J Asthma; 2012 May; 49(4):423-33. PubMed ID: 22380765
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Posaconazole: Use in the Prophylaxis and Treatment of Fungal Infections.
    Clark NM; Grim SA; Lynch JP
    Semin Respir Crit Care Med; 2015 Oct; 36(5):767-85. PubMed ID: 26398542
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Posaconazole.
    Keating GM
    Drugs; 2005; 65(11):1553-67; discussion 1568-9. PubMed ID: 16033292
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Posaconazole as salvage treatment of invasive fungal infections in patients with underlying renal impairment.
    Hachem RY; Langston AA; Graybill JR; Perfect JR; Pedicone LD; Patino H; Raad II
    J Antimicrob Chemother; 2008 Dec; 62(6):1386-91. PubMed ID: 18835806
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Posaconazole liquid vs tablet formulation in lung transplant recipients.
    Stelzer D; Weber A; Ihle F; Matthes S; Ceelen F; Zimmermann G; Kneidinger N; Schramm R; Winter H; Zoller M; Vogeser M; Behr J; Neurohr C
    Mycoses; 2018 Mar; 61(3):186-194. PubMed ID: 29110351
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Posaconazole for chronic pulmonary aspergillosis: the next strategy against the threat of azole-resistant Aspergillus infection.
    Kohno S; Izumikawa K
    Clin Infect Dis; 2010 Dec; 51(12):1392-4. PubMed ID: 21054178
    [No Abstract]   [Full Text] [Related]  

  • 38. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial.
    Walsh TJ; Raad I; Patterson TF; Chandrasekar P; Donowitz GR; Graybill R; Greene RE; Hachem R; Hadley S; Herbrecht R; Langston A; Louie A; Ribaud P; Segal BH; Stevens DA; van Burik JA; White CS; Corcoran G; Gogate J; Krishna G; Pedicone L; Hardalo C; Perfect JR
    Clin Infect Dis; 2007 Jan; 44(1):2-12. PubMed ID: 17143808
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacologic and clinical evaluation of posaconazole.
    Moore JN; Healy JR; Kraft WK
    Expert Rev Clin Pharmacol; 2015 May; 8(3):321-34. PubMed ID: 25916666
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative survival and cost of antifungal therapy: posaconazole versus standard antifungals in the treatment of refractory invasive aspergillosis.
    Herbrecht R; Rajagopalan S; Danna R; Papadopoulos G
    Curr Med Res Opin; 2010 Oct; 26(10):2457-64. PubMed ID: 20822354
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.